Restructuring Costs

12 Months Ended

Dec. 31, 2016

Restructuring and Related Activities Disclosure [Text Block]

16. Restructuring Costs

The Company terminated the PROCEED trial in May 2014 after the interim futility analysis indicated that vintafolide did not demonstrate efficacy on the pre-specified outcome of progression-free survival for the treatment of PROC. As a result, the Company ceased its pre-launch commercial activities in Europe and implemented staff reductions in Europe and in the U.S. All employee and contract termination expenses were recorded and paid in the year ended December 31, 2014. The PROCEED trial termination expenses were paid over the years ended December 31, 2014, 2015 and 2016. At December 31, 2016, the Company had no remaining accrual balance related to the PROCEED trial termination.

The following table summarizes the restructuring accruals for the years ended December 31, 2014, 2015 and 2016:


	Employee and		PROCEED
	Contract		Trial
	Termination		Termination
	Accrual		Accrual		Total
Balance, January 1, 2014	$	—	$	—	$	—
Charges for the year ended December 31, 2014		1,300,000		4,100,000		5,400,000
Amounts paid in the year ended December 31, 2014		(1,300,000)		(2,800,000)		(4,100,000)
Balance, December 31, 2014	$	—	$	1,300,000	$	1,300,000
Balance, January 1, 2015		—		1,300,000		1,300,000
Revised estimates in the year ended December 31, 2015		—		134,000		134,000
Amounts paid in the year ended December 31, 2015		—		(1,387,400)		(1,387,400)
Balance, December 31, 2015	$	—	$	46,600	$	46,600
Balance, January 1, 2016	$	—	$	46,600	$	46,600
Revised estimates in the year ended December 31, 2016		—		(15,800)		(15,800)
Amounts paid in the year ended December 31, 2016		—		(30,800)		(30,800)
Balance, December 31, 2016	$	—	$	—	$	—